Charles Schwab Investment Management Inc. Makes New $183,000 Investment in Chimerix, Inc. (NASDAQ:CMRX)

Charles Schwab Investment Management Inc. purchased a new position in Chimerix, Inc. (NASDAQ:CMRX) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 52,657 shares of the biopharmaceutical company’s stock, valued at approximately $183,000. Charles Schwab Investment Management Inc. owned approximately 0.06% of Chimerix as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Assenagon Asset Management S.A. increased its holdings in Chimerix by 154.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company’s stock worth $2,846,000 after purchasing an additional 496,823 shares during the period. Stoneridge Investment Partners LLC boosted its stake in shares of Chimerix by 22.5% in the 4th quarter. Stoneridge Investment Partners LLC now owns 44,305 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 8,134 shares during the period. Peapod Lane Capital LLC acquired a new position in shares of Chimerix during the fourth quarter worth about $2,626,000. Valeo Financial Advisors LLC increased its stake in shares of Chimerix by 78.8% during the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company’s stock worth $509,000 after buying an additional 64,420 shares during the period. Finally, Palumbo Wealth Management LLC acquired a new stake in Chimerix in the fourth quarter valued at approximately $221,000. Institutional investors and hedge funds own 45.42% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on CMRX shares. Jefferies Financial Group reiterated a “hold” rating and set a $8.50 price target (down previously from $10.00) on shares of Chimerix in a report on Wednesday, March 5th. StockNews.com started coverage on shares of Chimerix in a research note on Monday. They set a “hold” rating for the company. Wedbush reissued a “neutral” rating and issued a $8.55 target price (up previously from $7.00) on shares of Chimerix in a report on Wednesday, March 5th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $8.55 price target (down from $11.00) on shares of Chimerix in a report on Wednesday, March 5th.

Insiders Place Their Bets

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the transaction, the chief executive officer now owns 609,603 shares of the company’s stock, valued at $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last 90 days, insiders have sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is currently owned by insiders.

Chimerix Stock Down 0.1 %

Shares of Chimerix stock opened at $8.50 on Wednesday. Chimerix, Inc. has a 52 week low of $0.75 and a 52 week high of $8.53. The firm’s 50 day moving average is $6.04 and its two-hundred day moving average is $3.23. The firm has a market capitalization of $797.33 million, a P/E ratio of -9.04 and a beta of 0.32.

Chimerix (NASDAQ:CMRX) last posted its earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. The company had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.31 million. As a group, research analysts expect that Chimerix, Inc. will post -0.99 earnings per share for the current fiscal year.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.